Cognition Historical Income Statement

CGTX Stock

USD 0.44 0.02 4.35%

Historical analysis of Cognition Therapeutics income statement accounts such as Interest Expense of 25.6 K, Selling General Administrative of 9.8 M or Total Revenue of 0.0 can show how well Cognition Therapeutics performed in making a profits. Evaluating Cognition Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cognition Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Cognition Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cognition Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cognition Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Cognition Stock please use our How to Invest in Cognition Therapeutics guide.

About Cognition Income Statement Analysis

Cognition Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cognition Therapeutics shareholders. The income statement also shows Cognition investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Cognition Therapeutics Income Statement Chart

At this time, Cognition Therapeutics' Other Operating Expenses is fairly stable compared to the past year. Total Operating Expenses is likely to rise to about 53.3 M in 2024, whereas Net Interest Income is likely to drop (33.8 K) in 2024.

Selling General Administrative Gross Profit Research Development Cost Of Revenue Reconciled Depreciation

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Cognition Therapeutics minus its cost of goods sold. It is profit before Cognition Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Cost Of Revenue

Cost of Revenue is found on Cognition Therapeutics income statement and represents the costs associated with goods and services Cognition Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most accounts from Cognition Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cognition Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cognition Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Cognition Stock please use our How to Invest in Cognition Therapeutics guide.At this time, Cognition Therapeutics' Other Operating Expenses is fairly stable compared to the past year. Total Operating Expenses is likely to rise to about 53.3 M in 2024, whereas Net Interest Income is likely to drop (33.8 K) in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	893K	28K	27K	25.7K
Depreciation And Amortization	93K	235K	96K	91.2K

Interest Expense Depreciation And Amortization

Cognition Therapeutics income statement Correlations

	Net Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Non Operating Income Net Other	Selling And Marketing Expenses
Net Interest Income		-0.49	-1.0	0.82	-0.89	0.83	-0.91	-0.82	-0.88	0.89	-0.87	0.85	0.83	0.85	-0.87	0.94	-0.46	-0.92	0.68	-0.67
Depreciation And Amortization	-0.49		0.49	-0.86	0.76	-0.7	0.79	0.74	0.09	-0.7	0.85	-0.73	-0.7	-0.73	0.84	-0.65	0.5	0.75	-0.53	0.52
Interest Expense	-1.0	0.49		-0.82	0.89	-0.83	0.91	0.82	0.88	-0.89	0.87	-0.85	-0.83	-0.85	0.87	-0.94	0.46	0.92	-0.69	0.68
Selling General Administrative	0.82	-0.86	-0.82		-0.9	0.8	-0.94	-0.89	-0.47	0.94	-0.96	0.92	0.8	0.92	-0.94	0.94	-0.47	-0.92	0.66	-0.53
Gross Profit	-0.89	0.76	0.89	-0.9		-0.92	0.98	0.9	0.67	-0.94	0.96	-0.96	-0.92	-0.96	0.98	-0.91	0.58	0.99	-0.78	0.74
Other Operating Expenses	0.83	-0.7	-0.83	0.8	-0.92		-0.94	-0.68	-0.71	0.86	-0.93	0.83	1.0	0.82	-0.94	0.83	-0.84	-0.89	0.91	-0.92
Operating Income	-0.91	0.79	0.91	-0.94	0.98	-0.94		0.87	0.68	-0.95	0.99	-0.93	-0.94	-0.93	0.99	-0.94	0.64	0.98	-0.8	0.76
Net Income From Continuing Ops	-0.82	0.74	0.82	-0.89	0.9	-0.68	0.87		0.49	-0.85	0.87	-0.91	-0.68	-0.91	0.87	-0.84	0.19	0.94	-0.44	0.44
Ebit	-0.88	0.09	0.88	-0.47	0.67	-0.71	0.68	0.49		-0.66	0.6	-0.59	-0.71	-0.59	0.61	-0.72	0.48	0.68	-0.65	0.68
Research Development	0.89	-0.7	-0.89	0.94	-0.94	0.86	-0.95	-0.85	-0.66		-0.94	0.98	0.86	0.98	-0.94	0.98	-0.55	-0.95	0.81	-0.59
Ebitda	-0.87	0.85	0.87	-0.96	0.96	-0.93	0.99	0.87	0.6	-0.94		-0.92	-0.93	-0.92	1.0	-0.92	0.64	0.96	-0.78	0.75
Cost Of Revenue	0.85	-0.73	-0.85	0.92	-0.96	0.83	-0.93	-0.91	-0.59	0.98	-0.92		0.83	1.0	-0.94	0.93	-0.46	-0.96	0.74	-0.56
Total Operating Expenses	0.83	-0.7	-0.83	0.8	-0.92	1.0	-0.94	-0.68	-0.71	0.86	-0.93	0.83		0.82	-0.94	0.83	-0.84	-0.89	0.91	-0.92
Reconciled Depreciation	0.85	-0.73	-0.85	0.92	-0.96	0.82	-0.93	-0.91	-0.59	0.98	-0.92	1.0	0.82		-0.93	0.93	-0.45	-0.96	0.73	-0.55
Income Before Tax	-0.87	0.84	0.87	-0.94	0.98	-0.94	0.99	0.87	0.61	-0.94	1.0	-0.94	-0.94	-0.93		-0.91	0.65	0.97	-0.79	0.76
Total Other Income Expense Net	0.94	-0.65	-0.94	0.94	-0.91	0.83	-0.94	-0.84	-0.72	0.98	-0.92	0.93	0.83	0.93	-0.91		-0.5	-0.93	0.75	-0.57
Net Income	-0.46	0.5	0.46	-0.47	0.58	-0.84	0.64	0.19	0.48	-0.55	0.64	-0.46	-0.84	-0.45	0.65	-0.5		0.5	-0.9	0.87
Income Tax Expense	-0.92	0.75	0.92	-0.92	0.99	-0.89	0.98	0.94	0.68	-0.95	0.96	-0.96	-0.89	-0.96	0.97	-0.93	0.5		-0.71	0.69
Non Operating Income Net Other	0.68	-0.53	-0.69	0.66	-0.78	0.91	-0.8	-0.44	-0.65	0.81	-0.78	0.74	0.91	0.73	-0.79	0.75	-0.9	-0.71		-0.8
Selling And Marketing Expenses	-0.67	0.52	0.68	-0.53	0.74	-0.92	0.76	0.44	0.68	-0.59	0.75	-0.56	-0.92	-0.55	0.76	-0.57	0.87	0.69	-0.8

Click cells to compare fundamentals

Cognition Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GOOG	Alphabet Inc Class C
CRM	Salesforce

Additional Tools for Cognition Stock Analysis

When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cognition Historical Income Statement

About Cognition Income Statement Analysis

Cognition Therapeutics Income Statement Chart

Gross Profit

Cost Of Revenue

Cognition Therapeutics income statement Correlations

Cognition Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Cognition Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Other Operating Expenses
Income Before Tax	+ 1.0	Ebitda
Reconciled Depreciation	+ 1.0	Cost Of Revenue
Income Tax Expense	+ 0.99	Gross Profit
Ebitda	+ 0.99	Operating Income
Income Before Tax	+ 0.99	Operating Income

Interest Expense	- 1.0	Net Interest Income
Income Tax Expense	- 0.96	Reconciled Depreciation
Income Tax Expense	- 0.96	Cost Of Revenue
Reconciled Depreciation	- 0.96	Gross Profit
Cost Of Revenue	- 0.96	Gross Profit
Ebitda	- 0.96	Selling General Administrative